Larimar Therapeutics (LRMR) Research & Development (2013 - 2025)

Larimar Therapeutics' Research & Development history runs 13 years deep, the most recent figure standing at $59.4 million for Q4 2025.

• Quarterly Research & Development rose 122.05% year-over-year to $59.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $154.2 million (up 110.46% YoY) and the FY2025 annual result came in at $154.2 million, up 110.46% from the prior year.
• Research & Development was $59.4 million for Q4 2025 at Larimar Therapeutics, up from $44.9 million in the prior quarter.
• Across five years, Research & Development topped out at $59.4 million in Q4 2025 and bottomed at $4.6 million in Q1 2023.
• A 5-year average of $15.9 million and a median of $9.9 million in 2021 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development plunged 60.21% — and 2024, when it soared 235.01%.
• Larimar Therapeutics' Research & Development stood at $6.3 million in 2021, then climbed by 14.72% to $7.2 million in 2022, then soared by 47.52% to $10.6 million in 2023, then soared by 151.11% to $26.7 million in 2024, then surged by 122.05% to $59.4 million in 2025.
• Business Quant data shows LRMR's Research & Development at $59.4 million in Q4 2025, $44.9 million in Q3 2025, and $23.4 million in Q2 2025.